DD
"DuPont split off its electronics business, divested aramids, and is deploying a Danaher-style business system while the stock sits 31% below its highs. Is 'New DuPont' a misunderstood multi-industrial trading at a chemical discount, or does legacy PFAS exposure and construction weakness justify the markdown?"
DuPont de Nemours is a $17.4B diversified specialty materials company that completed its transformation in late 2025 by separating Cunity Electronics. The remaining 'New DuPont' generates ~$6.84B in revenue across two segments: Healthcare & Water Technologies (31% EBITDA margins, mid-single-digit organic growth) and Diversified Industrials (23% margins, recovery phase). The company guides 3% organic growth and 60-80bps of margin expansion for 2026, with medium-term targets of 150-200bps margin expansion over 2026-2028. Key assets include leading water filtration technology (RO, IX, UF), the Tyvek franchise, and medical packaging/device positions. PFAS legacy liabilities are shared with Corteva and Chemours under a cost-sharing agreement.
Executive Summary
Cross-lens roll-up assessment
DuPont presents as a portfolio transformation story entering its operational execution phase. The 'New DuPont' that emerged from the Cunity separation has genuinely attractive core assets: leading water filtration technology serving a secular growth market, the Tyvek franchise with pricing power and 30% vitality index, and healthcare positions benefiting from cardiovascular procedure growth. The 24% EBITDA margin with 100bps annual expansion, 1.7x net leverage, and strong management alignment create a credible multi-industrial profile. However, PFAS legacy liabilities represent a material contingency that is inherently difficult to bound, construction market weakness depresses ~25% of revenue, and the Danaher-style business system is in its infancy. The chemical-company valuation discount may narrow with GICS reclassification, but operational proof points are still needed.
DuPont's strong balance sheet, leading market positions, and management alignment support a constructive view. The PFAS liability and construction weakness create real uncertainty, but the portfolio transformation positions the company for re-rating if operational execution continues. The 2026 guidance is achievable based on current trajectories. The primary risk is that PFAS liabilities prove larger than expected or that the business system deployment stalls. Position sizing should reflect the PFAS contingency risk.
Key Takeaways
- •CAPITAL_DEPLOYMENT is DISCIPLINED (E2): Cunity separation received $4.2B midnight dividend, Aramis fetching $1.2B, and $500M ASR completed. M&A pipeline focused on healthcare CDMO and water with explicit ROIC > WACC by year 5 hurdle. Capital allocation framework is well-articulated and consistently executed.
- •FUNDING_FRAGILITY is STABLE (E2): Pro forma net debt/EBITDA at 1.7x with target below 2x. $3.25B debt with no near-term maturities flagged. $1B cash target, >90% FCF conversion. Aramis proceeds provide additional flexibility. Balance sheet is a clear strength.
- •REVENUE_DURABILITY is CONDITIONAL (E2): Healthcare & Water segment growing mid-single digits on secular tailwinds is durable. Diversified Industrials depends on cyclical construction recovery and auto builds. The 50/50 mix means half the portfolio has fragile near-term growth drivers.
- •COMPETITIVE_POSITION is DEFENSIBLE (E3): Leading positions in RO, IX, UF water filtration with Gen 4 technology advancing. Tyvek franchise with pricing power and new APX garment launch. Medical packaging and device positions in high-growth cardiovascular space. Innovation engine at 30% vitality index with 145bps margin lift from new products.
- •REGULATORY_EXPOSURE is ELEVATED (E2): PFAS cost-sharing with Corteva and Chemours creates quantifiable but hard-to-bound liability. EPA drinking water regulations simultaneously increase DuPont's cleanup costs and drive demand for its water filtration products. Net impact is uncertain.
- •OPERATIONAL_EXECUTION is MEETING (E2): Beat FY2025 guidance with raise, delivered 6% EBITDA growth and 100bps margin expansion. Business system in early deployment with enhanced KPIs and lean methodology. 80/20 framework not yet contributing to results.
Key Tensions
- •PFAS liability simultaneously threatens the balance sheet through environmental cleanup costs while driving demand for DuPont's water filtration products. The same EPA regulations that increase liability also expand the addressable market for RO and IX membranes. Models disagreed on whether the net exposure is positive or negative.
- •The Danaher-style business system is the linchpin of the margin expansion thesis (150-200bps over 3 years), but DuPont has only recently hired the key operators (Cook from Danaher, Ferreira from ITW). Converting a legacy chemical company culture to continuous improvement is a multi-year effort with uncertain outcomes.
- •DuPont trades at chemical-company multiples (~10-12x EBITDA) while management argues the portfolio deserves multi-industrial multiples (~14-16x). GICS reclassification could mechanically drive index fund rebalancing, but the timeline is uncertain and the market may not rerate without sustained operational outperformance.
Consolidation Calibrator
Is this acquisition strategy creating or destroying value?
Key Metrics
Key FindingsClick to expand details
Signal AssessmentsClick for full context
| Signal | Scale | Assessment | Evidence |
|---|---|---|---|
Capital Deployment | — | DISCIPLINED | 2Corroborated |
Accounting Integrity | — | CLEAN | 2Corroborated |
Model Debates
Cross-Lens Insights
Where Lenses Agree
- Balance sheet strength is confirmed across all lenses — 1.7x leverage provides strategic flexibility
- Healthcare & Water Technologies is a genuinely high-quality business growing on secular tailwinds
- The Danaher-style business system is promising but unproven — proof points needed in 2026
Where Lenses Differ
REGULATORY_EXPOSURE
The Regulatory Reader flags PFAS as an ELEVATED risk due to uncertain total liability. The Stress Scanner classifies funding as STABLE because the current balance sheet can absorb expected costs. Both can be true simultaneously — the balance sheet is strong today but faces a tail risk that could change the calculus.
The following publicly available documents were collected and extracted into a structured fact dossier that powered this analysis.
SEC Filing
- Annual Report (10-K) — FY2025
- Quarterly Report (10-Q) — Q3 2025
- Quarterly Report (10-Q) — Q2 2025
- Quarterly Report (10-Q) — Q1 2025
- Quarterly Report (10-Q) — Q3 2024
- Proxy Statement (DEFA14A) — 2025
- Current Reports (8-K) — 10 filings, Oct 2025 to Mar 2026
- Form 4 Insider Transactions — 20 filings
- Form 144 Proposed Sales — 10 filings
Earnings Transcript
- Q4 2025 Earnings Call Transcript
- Q3 2025 Earnings Call Transcript
- Q2 2025 Earnings Call Transcript
- Q1 2025 Earnings Call Transcript
Research Document
- CourtListener Litigation — DuPont de Nemours (10 cases)